Ardent Health (NYSE:ARDT) Rating Lowered to “Buy” at Wall Street Zen

Ardent Health (NYSE:ARDT) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other research firms also recently issued reports on ARDT. Bank of America reduced their price target on shares of Ardent Health from $12.00 to $10.00 and set an “underperform” rating for the company in a research report on Thursday. Stephens decreased their target price on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Friday. Leerink Partners set a $16.00 price objective on shares of Ardent Health in a research note on Friday. UBS Group initiated coverage on Ardent Health in a research report on Wednesday, September 10th. They set a “buy” rating and a $17.00 price target for the company. Finally, The Goldman Sachs Group started coverage on shares of Ardent Health in a research note on Tuesday, October 14th. They issued a “neutral” rating and a $19.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Ardent Health has a consensus rating of “Moderate Buy” and a consensus target price of $15.92.

Ardent Health Stock Down 2.8%

ARDT stock opened at $9.04 on Friday. Ardent Health has a twelve month low of $8.85 and a twelve month high of $17.91. The stock has a market cap of $1.29 billion, a P/E ratio of 6.23, a PEG ratio of 5.03 and a beta of 0.44. The company has a current ratio of 2.13, a quick ratio of 2.00 and a debt-to-equity ratio of 0.66. The company’s 50 day moving average is $13.80 and its two-hundred day moving average is $13.35.

Ardent Health (NYSE:ARDT) last announced its earnings results on Wednesday, November 12th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.10. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.55 billion. Ardent Health had a net margin of 3.24% and a return on equity of 19.19%. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Research analysts expect that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ardent Health

Institutional investors have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Ardent Health in the first quarter worth approximately $469,000. SageView Advisory Group LLC bought a new position in Ardent Health during the first quarter valued at about $2,327,000. Strs Ohio bought a new position in shares of Ardent Health in the 1st quarter valued at approximately $494,000. Vanguard Group Inc. lifted its stake in shares of Ardent Health by 368.9% in the first quarter. Vanguard Group Inc. now owns 1,330,635 shares of the company’s stock worth $18,296,000 after buying an additional 1,046,845 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in Ardent Health during the 1st quarter worth $1,537,000.

Ardent Health Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.